
Figure 1




BILF2 antibodies (n=8)
28H9 supernatant dialyzed
27H11 supernatant dialyzed
25A2 purified
26G5 purified
27F5 purified
28H3 purified
28F8 purified
9B8 purified

control antibodies (n=7)
25G11 supernatant sterile
26B5 supernatant sterile
6H9 supernatant dialyzed
12G11 supernatant dialyzed
20B9 supernatant dialyzed
16A1 supernatant dialyzed
1D2 purified

RLU = relative light units; normalized to 100%

Figure 2



BILF2 antibodies (n=8)
28H9 supernatant dialyzed
27H11 supernatant dialyzed
25A2 purified
26G5 purified
27F5 purified
28H3 purified
28F8 purified
9B8 purified

control antibodies (n=7)
25G11 supernatant sterile
26B5 supernatant sterile
6H9 supernatant dialyzed
12G11 supernatant dialyzed
20B9 supernatant dialyzed
16A1 supernatant dialyzed
1D2 purified

% infected HEK293 cells normalized to 100%

Figure 3



EBV positive donors
EBV negative donors
26G5
27F5
28H3
9B8
% positive cells
Dilution

Figure 4



BILF2 serum antibodies
10,000
1,000
100
Titer 1:10
1
day 1
day 61
day 75
day of serum collection
BILF2 DNA
BILF2 mRNA
BILF2 protein
BILF2 EVs

Figure 5




Figure 6

